Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
Guigang
HCV
ageing
microclearance
telemedicine
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
08
01
2024
received:
19
12
2023
accepted:
13
01
2024
medline:
18
3
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) represents a formidable menace to human health, necessitating urgent attention. The objective of this study was to assess the efficacy and safety of HCV health management in the city of Guigang which consists of five districts, employing a comprehensive multi-modal approach. The study systematically carried out HCV screening in Guigang city which consists of five districts, such as Gangbei District, Gangnan District, Guiping District, Qintang District, and Pingnan District from 1 January 2016 to 30 December 2022. The target population consisted of individuals residing in these aforementioned districts, falling within the age range of 30-75 years. A multidisciplinary HCV management team was established to deliver anti-HCV screening, diagnosis, and direct-acting antiviral (DAA) therapy. The primary outcome of interest was the achievement of sustained virologic response (SVR). A total of 2489 individuals were included as the target population, with 1694 individuals residing in Gangbei District, 202 in Gangnan District, 111 in Qintang District, 167 in Pingnan District, and 315 in Guiping District. Out of these individuals, 2478 were subjected to anti-HCV screening. The screening rates varied across the districts, ranging from a peak of 99.55% in Guigang City to a nadir of 98.41% in Guiping District. Remarkably, within Guigang City, a noteworthy enhancement was observed in the HCV-RNA diagnosis rate from 23.4% prior to program implementation to a remarkable 100% following 7 years of intervention and management. Furthermore, the diagnosis and treatment coordination rate experienced a substantial improvement, rising from 26.8% before program inception to 80%. Importantly, a total of 1180 individuals affected by hepatitis C were successfully cured, equating to a 100% cure rate. Logistic regression analysis revealed a significant association between serological status and factors such as Aging, bilirubin, and glutamic oxalacetic transaminase. The findings from our investigation unveil a pioneering HCV management model, exemplified by the Guigang model, which has contributed crucially to HCV microclearance efforts and serves as an invaluable reference for future initiatives.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-215Subventions
Organisme : Guigang City Science Research and Technology Development Plan Project Contract
ID : 2117016
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Krekulova L, Honzák R, Riley LW. Viral hepatitis C pandemic: challenges and threats to its elimination. J Viral Hepat. 2021;28:694-698.
Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8:332-342.
Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet. 2019;58:1237-1263.
Stahlman SL, Hsu NM, Mancuso JD. Viral hepatitis C, active component, U.S. armed forces, 2011-2020. MSMR. 2022;29:2-7.
Yasseen AS 3rd, Kwong JC, Feld JJ, et al. Viral hepatitis C cascade of care: a population-level comparison of immigrant and long-term residents. Liver Int. 2021;41:1775-1788.
Braczkowska B, Kowalska M, Barański K, Mendera-Bożek U. Viral hepatitis C in Poland in the Silesian Province between 2005-2014. Ann Agric Environ Med. 2017;25:224-228.
Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-9280.
Dhingra S, Ward SC, Thung SN. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol. 2016;22:1357-1366.
Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011;31(Suppl 2):1-3.
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562.
Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination-a path to global elimination of hepatitis C. J Hepatol. 2017;67:665-666.
Dawson GJ. The potential role of HCV core antigen testing in diagnosing HCV infection. Antivir Ther. 2012;17:1431-1435.
Lee HW, Lee H, Kim BK, Chang Y, Jang JY, Kim DY. Cost-effectiveness of chronic hepatitis C screening and treatment. Clin Mol Hepatol. 2022;28:164-173.
Youssef SS, Elemeery MN, Eldein SS, Ghareeb DA. Silencing HCV replication in its reservoir. Open Access Maced J Med Sci. 2018;6:1965-1971.
He QF, Zhang QF, Zhang DZ. Efficacy and safety of ribavirin with sofosbuvir plus ledipasvir in patients with genotype 1 hepatitis C: a meta-analysis. Dig Dis Sci. 2016;61:3108-3117.
Yu ML, Chen PJ, Dai CY, et al. Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020;119:1019-1040.
Carloni G, Crema A, Valli MB, Ponzetto A, Clementi M. HCV infection by cell-to-cell transmission: choice or necessity? Curr Mol Med. 2012;12:83-95.
Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in primary care settings. J Gen Intern Med. 2018;33:551-557.
Yu ML, Huang CF, Wei YJ, et al. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut. 2021;70:2349-2358.
Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci. 2019;14:26.
Lazarus JV, Stumo SR, Harris M, et al. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. J Int AIDS Soc. 2018;21(Suppl 2):e25052.
Li W, Chang TS, Chang SZ, Chen CH, Chen MY. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach. BMC Infect Dis. 2020;20:737.
Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264-1278.e1264.
Tsai PC, Kuo HT, Hung CH, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2023;78:281-292.
Huang CF, Wu PF, Yeh ML, et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clin Mol Hepatol. 2021;27:136-143.
Wei YJ, Hsu PY, Lee JJ, et al. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-like group. J Viral Hepat. 2021;28:719-727.
Cabezas J, Llerena S, Crespo J. Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs in reference to: chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience, by Pérez Hernández et al. Rev Esp Enferm Dig. 2021;113:623-624.
Doica IP, Florescu DN, Oancea CN, et al. Telemedicine chronic viral hepatitis C treatment during the lockdown period in Romania: a pilot study. Int J Environ Res Public Health. 2021;18:3694.
Kracht PAM, Arends JE, van Erpecum KJ, et al. REtrieval and cure of chronic hepatitis C (REACH): results of micro-elimination in the Utrecht province. Liver Int. 2019;39:455-462.
Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (extension for community healthcare outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37:20-24.
Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-2207.
Tran L, Feldman R, Riley T 3rd, Jung J. Association of the Extension for community healthcare outcomes project with use of direct-acting antiviral treatment among US adults with hepatitis C. JAMA Netw Open. 2021;4:e2115523.
Shiha G, Metwally AM, Soliman R, Elbasiony M, Mikhail NNH, Easterbrook P. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project. Lancet Gastroenterol Hepatol. 2018;3:778-789.
Shiha G, Soliman R, Mikhail NNH, Easterbrook P. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: feasibility and effectiveness in 73 villages. J Hepatol. 2020;72:658-669.
Astegiano M, Sapone N, Demarchi B, Rossetti S, Bonardi R, Rizzetto M. Laboratory evaluation of the patient with liver disease. Eur Rev Med Pharmacol Sci. 2004;8:3-9.
Tan G, Yuan R, Hao Z, et al. Liver function indicators performed better to eliminate cardioembolic stroke than to identify it from stroke subtypes. J Stroke Cerebrovasc Dis. 2017;26:230-236.